A5045806536- Inflammatory Bowel Disease
- Microscopic Colitis
- Autoimmune and Inflammatory Disorders Research
- Helicobacter pylori-related gastroenterology studies
- Autoimmune and Inflammatory Disorders
- Ultrasound in Clinical Applications
- Pharmacological Effects and Toxicity Studies
- Financial Reporting and XBRL
- Epilepsy research and treatment
- Eosinophilic Esophagitis
- Diagnosis and treatment of tuberculosis
- Gastrointestinal disorders and treatments
- Nutrition and Health in Aging
- Gastrointestinal Tumor Research and Treatment
- Biosimilars and Bioanalytical Methods
- Diverticular Disease and Complications
- IgG4-Related and Inflammatory Diseases
- Organizational Change and Leadership
- Anorectal Disease Treatments and Outcomes
- Service-Learning and Community Engagement
- Health Systems, Economic Evaluations, Quality of Life
- Human Resource Development and Performance Evaluation
- Restraint-Related Deaths
- Accounting Education and Careers
- Diagnosis and Treatment of Venous Diseases
Mater Adult Hospital
2023-2025
Mater Hospital
2025
The University of Queensland
2023-2024
Mater Research
2023-2024
Austin Health
2020-2023
Northern Health
2022-2023
Urology of Virginia
2023
St Vincent's Hospital
2023
Alfred Health
2020
Abstract Background and Aims Acute severe ulcerative colitis [ASUC] is a medical emergency treated with intravenous steroids followed by infliximab or cyclosporin in the case of steroid failure emergent colectomy required refractory cases. Case series have reported on effectiveness tofacitinib for disease, but data regarding upadacitinib this setting not been previously reported. We describe use therapy steroid-refractory ASUC patients prior loss response to infliximab. Methods Six who...
Preliminary data regarding the effectiveness of tofacitinib in acute severe ulcerative colitis [ASUC] have been presented two previous case series. We aimed to describe novel use high-dose immediately following non-response infliximab setting steroid-refractory ASUC.Five patients who received 10 mg three times a day for ASUC were identified at an Australian tertiary inflammatory bowel disease centre.Four five demonstrated clinical response induction during their inpatient admission, with one...
Abstract Background Acute Severe Ulcerative Colitis (ASUC) is a medical emergency, with limited therapeutic options available for management. Tofacitinib and Upadacitinib are novel Janus Kinase inhibitors (JAKi), proven efficacy ulcerative colitis (UC). This study aimed to examine the outcomes of patients treated JAKi ASUC in real-world population. Methods A retrospective multi-centre was conducted including (≥18 years) commenced on or from April 2021 2024. defined according Truelove Witt’s...
Abstract Background Intestinal ultrasound has revolutionised inflammatory bowel disease (IBD) care, as a quick, cost-effective, accurate and reliable tool for assessing IBD activity. Recently high-quality handheld devices (HHUS) have emerged, representing more accessible, cheaper alternative to expensive cumbersome cart-based ultrasounds (CBUS), however their accuracy IUS not been studied. We aimed assess the of HHUS compared CBUS in real-world population. Methods prospectively recruited...
Abstract Background There are limited comparisons of clinical outcomes acute severe ulcerative colitis (ASUC) between East Asian (EA) and Western countries many currently used scoring systems based on populations. We developed a predictive model using ASUC data from EA patients assessed its ability to predict in an Australia/New Zealand (ANZ) cohort. Methods This retrospective international study was conducted across 23 referral hospitals ANZ. Patients who met Truelove Witts criteria for...
BACKGROUND Chronic pouchitis remains a significant and prevalent complication following ileal pouch-anal anastomosis in patients with ulcerative colitis. AIM To identify potential risk factors for the development of chronic pouchitis. METHODS Predictors were investigated through systematic review meta-analysis. A comprehensive search Medline, EMBASE, PubMed databases was undertaken to relevant studies published up October 2023. Meta-analytic procedures employed random-effects models...
Background and study aims Foreign body ingestion is a common cause for Emergency Department presentation. In adults, foreign more in patients with underlying psychiatric comorbidity, the elderly, alcohol intoxication, prisoners. This reviewed management of presenting to tertiary hospital ingestion. Patients methods A retrospective review Melbourne, Victoria, was undertaken from January 2017 December 2021. Data collected included patient demographics, type body, length stay, imaging...
Anti-tumor necrosis factor (TNF) dose intensification represents an effective method of overcoming secondary loss response (LOR); however, a subset patients may not respond (tertiary non-response), or fail to demonstrate durable LOR) intensified dosing. This systematic review and meta-analysis aimed evaluate these outcomes determine the clinical effectiveness empiric in Crohn's disease.Multiple databases including MEDLINE EMBASE were interrogated identify studies that reported following...
Abstract Background Upadacitinib is a novel selective Janus Kinase (JAK) inhibitor which has recently been approved for use in ulcerative colitis. Clinical trials have rigorous criteria and excluded patients with prior exposure to JAK inhibitors. Given limited real-world effectiveness data we examined outcomes of treated upadacitinib colitis population, focus on tofacitinib exposure. Methods This retrospective, multi-centre study recruited commencing moderate-to-severe from September 2022...
Abstract Background Timely inflammatory bowel disease (IBD) flare treatment improves outcomes, but quick differentiation from other symptom causes is challenging. We aimed to reduce unplanned hospital presentations with a novel IBD clinical care pathway (CCP) allowing appropriate early management, utilising nurse-led triage and objective assessment rapid access intestinal ultrasound (RAIUS). Methods Prospective data collection 15 November 2022 until 14 June 2023, including pre-specified...
Background/AimsUpadacitinib is a novel selective Janus kinase inhibitor approved for use in ulcerative colitis. Clinical trials had rigorous criteria and excluded many patient subgroups. Given limited real-world effectiveness data, we examined outcomes of patients treated with upadacitinib colitis population. MethodsPatients that commenced moderate-to-severe from September 2022 until March 2023 were identified at 13 inflammatory bowel disease centers across Australia. Clinical, biochemical,...
A substantial proportion of patients with inflammatory bowel disease (IBD) on intravenous infliximab require dose intensification. Accessing additional is labour-intensive and expensive, depending insurance pharmaceutical reimbursement. Observational data suggest that subcutaneous may offer a convenient safe alternative to maintain remission in requiring dose-intensified infliximab. prospective, controlled trial required confirm as effective infliximab, identify predictors flare establish...
Abstract Background and Aim Acute severe ulcerative colitis (ASUC) remains a significant cause of morbidity healthcare utilization. This study aimed to characterize the total costs ASUC, explore factors associated with cost over 12 months following an index admission, document outcomes including corticosteroid exposure. Methods Patients admitted from January 2016 until 2021 for ASUC tertiary inflammatory bowel disease (IBD) center in Australia were identified via retrospective chart review....
Background: Endoscopic balloon dilatation (EBD) is an alternative therapy to avoid or delay surgery in stricturing Crohn’s disease (CD); however, certain factors determining outcomes remain poorly defined, and conflicting evidence exists current studies. In one of the largest cohorts date, we assess following EBD for CD both anastomotic de novo strictures. Methods: A retrospective cohort study patients undergoing was conducted at 12 hospitals across Australia New Zealand. Local databases...
Acute severe ulcerative colitis (ASUC) represents a medical emergency associated with high mortality and morbidity. While corticosteroids are the primary treatment, cases that unresponsive often require rescue therapy either infliximab or cyclosporine to reduce rate of colectomy. Janus kinase inhibitors, such as tofacitinib upadacitinib, highly efficacious rapid induction clinical response in moderate (UC). Limited data available on its use ASUC. We present first case utilizing upadacitinib...